| 1403GCC |
An Umbrella Protocol for Collection of Blood, Tumor Tissue, Lymph Node Specimens,
normal tissue, effusions CSF fluid and Buccal Samples from Patients with Established
or Suspected Solid Tumor Malignancy and Normal Subjects, to be used in Laboratory
Research |
Open |
| 19108GCCC |
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability,
Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid
Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) |
Open |
| 19140GCCC |
PILOT STUDY OF LASER INTERSTITIAL THERMAL THERAPY FOLLOWED BY HYPOFRACTIONATED RADIATION
THERAPY FOR RECURRENT HIGH GRADE GLIOMAS |
Open |
| 1950GCCC |
First in Human Phase 1A (dose escalation) and I B (expansion cohorts) Study of [IND
# Agent-AG01 a Chimeric Monoclonal Antibody against Glycoprotein GP88] in advanced
Solid Tumor Malignancies (1A) with expansion cohorts (1B) in advanced Triple Negative
Breast Cancer, Hormone Resistant Breast Cancer, advanced Non-small Cell Lung Cancer
(NSCLCA) and advanced Mesothelioma |
Open |
| 20138GCC |
LASER INTERSTITIAL THERMAL THERAPY FOLLOWED BY HYPOFRACTIONATED RADIATION THERAPY
FOR TREATMENT OF NEWLY DIAGNOSED HIGH-GRADE GLIOMAS |
Open |
| 22110GCCC |
Imaging Tumors with Hyperpolarized Carbon-13 Pyruvate ( HP-00101177) |
Open |
| 2221GCCC |
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics,
and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced
MTAP-null Solid Tumors |
Open |
| 2230GCCC |
BT012:A randomized pivotal study assessing the efficacy of targeted blood-brain barrier
(BBB) disruption using Exablate focused ultrasound during the standard of care treatment
of brain metastases of non-small cell lung cancer (NSCLC) origin |
Open |
| 2250GCCC |
A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate
Model 4000 using Microbubble Resonators to Temporarily Mediate
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects
with Glioblastoma Brain Tumors (BT015) |
Open |
| 24116GCCC |
24116GCCC: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune®
(TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus
Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of
Newly Diagnosed Glioblastoma |
Open |
| 2415GCCC |
REMASTer: REcurrent brain Metastases After SRS Trial |
Open |
| 2422GCCC |
Phase I Feasibility and Pilot RCT of Serious Illness Conversation Guide in Patient
and Intimate Partner Dyads Living with Advanced Lung Cancer
|
Open |
| 2577GCCC |
Evaluating if increased vascularity on Brain Magnetic Resonance Imaging correlates
with poor prognosis in Glioblastoma patients |
Open |
| ANBL1531 |
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to
Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) |
Open |
| ANBL2131 |
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children
with Newly Diagnosed High-Risk Neuroblastoma |
Open |
| EAY191-N5 |
A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination With
Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other
Solid Tumors |
Open |
| NRG-BN011 |
A Phase III Trial of Lomustine-Temozolomide Combination
Therapy Versus Standard Temozolomide in Patients with Methylated MGMT
Promoter Glioblastoma |
Open |
| NRG-BN013 |
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated
SRS (FSRS) for Intact Brain Metastases |
Open |
| NRG-CC009 |
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant
Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell
Lung Cancer
|
Open |
| NRG-CC014 |
Radiation Therapy for High-Risk Asymptomatic Bone
Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical
Trial (PREEMPT) |
Open |